82% of Global LPs to Increase Exposure to Private Credit in Next Three Years, CSC Research Finds
23.9.2025 15:00:00 CEST | Business Wire | Press Release
More than four fifths (82%) of limited partners (LPs) say they expect to increase allocations to private credit over the next three years, according to a new international study by CSC, the leading provider of global business administration and compliance solutions. Of these LPs, around two fifths (42%) expect “significant” growth in private credit exposure, underscoring the momentum and positive investor sentiment towards the asset class.
The research that canvassed the views of 300 general partners (GPs) and 200 limited partners (LPs) in Europe, Asia Pacific, and North America, found that portfolio diversification was the primary motive behind greater allocation (according to 76% of LPs), ahead of attractive returns (36%).
Private credit GPs are also bullish. The study, commissioned by CSC to inform its new report, “Private Credit 2025: Scaling Global Strategies Through Operational Excellence,” found three fifths (59%) of GPs forecasting AUM growth of 6–10% over a three-year horizon and 31% expecting growth above 10%.
“Private credit has exploded into the mainstream, becoming a truly global, multijurisdictional phenomenon that looks set to attract more and more investor capital,” said Marshall Saffer, managing director, Funds and Capital Markets at CSC. “As a business, we’re seeing first-hand how private credit has evolved, including innovation in structuring and cross-border strategies, and we’re well positioned to help GPs capitalize on strong demand.”
Growth driven by strategy shifts and cross-border expansion
CSC’s study found senior debt and asset-backed finance emerging as the most attractive underlying strategies, with distressed debt ranked lowest in expected growth. Cross-border lending is another major growth area, with 79% of GPs expecting international activity to increase significantly.
However, as the private credit sector grows, administrative complexity is increasingly taking its toll, especially for cross-border strategies where reporting, risk transparency, and operational readiness are under greater scrutiny.
“Private credit’s fast growth presents implicit challenges to operating models for fund managers, and imposes considerable demands on them and other stakeholders, particularly when investing in multiple jurisdictions and across borders,” said Constantinos Kleanthous, managing director, APAC at CSC. “As our study found, GPs have voted with their feet when it comes to outsourcing operational support to dedicated third-party specialists—and even more for functions like loan agency.”
CSC’s report found that 91% of LPs believe GPs who outsource to specialist service providers deliver enhanced reporting. Respondents cited SPV administration, collateral management, and loan agency as crucial in managing fund complexity and enhancing transparency.
As private credit cements its place in global portfolios, the research makes clear that growth must be matched with operational strength. GPs with the right infrastructure, and the right specialist partners will be best placed to seize the opportunity ahead.
For a full copy of “Private Credit 2025: Scaling Global Strategies Through Operational Excellence,” download it at cscglobal.com/service/campaigns/private-credit-2025.
About CSC
CSC is the trusted partner of choice for more than 90% of the Fortune 500®, more than 90% of the 100 Best Global Brands (Interbrand®), and more than 70% of the PEI 300. We are the world’s leading provider of global business administration and compliance solutions, specialized administration services to alternative asset managers across a range of fund strategies, transactions involving capital markets participants in both public and private markets, domain name system management and digital brand and fraud protection, and corporate tax software solutions. Founded in 1899 and headquartered in Wilmington, Delaware, USA, CSC prides itself on being privately held and professionally managed for more than 125 years. CSC has office locations and capabilities in more than 140 jurisdictions across Europe, the Americas, Asia Pacific, and the Middle East. We are a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. We are the business behind business®. Learn more at cscglobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250923262106/en/
Contacts
Citigate Dewe Rogerson (CDR)
Hassan Ali | Thomas Dalton
cscteam@cdrconsultancy.com
CSC
Laura Crozier
PR Manager
laura.crozier@cscglobal.com
CSC News Room -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fservice%2Fpress%2F&esheet=54327702&newsitemid=20250923262106&lan=en-US&anc
hor=CSC+News+Room&index=3&md5=244f3b008c79b0d54ac0f3135440b491
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom